OR WAIT null SECS
September 18, 2026
Video
Josh Woolley, MD, PhD, says active placebos fail to mask high-dose psilocybin and propose combining drug classes with authorized incomplete disclosure.
September 17, 2026
In his paper, Josh D. Woolley, MD, PhD, proposes multidrug active placebos and limited disclosure to finally mask high-dose psilocybin trials.
September 01, 2026
Article
A regulatory resubmission, 2 phase 3 psychedelic trial readouts, new TMS dosing data, and an MDD genetics study, all in this August 2026 recap.
August 10, 2026
Resilient Pharmaceuticals has resubmitted its MDMA-assisted therapy NDA for PTSD without a new phase 3 trial, MAPS reported.
April 23, 2026
Alva outlines how general clinicians should address patient questions on psychedelic therapies, including risks, approvals, and referral pathways.
April 22, 2026
Alva discusses infrastructure gaps, training demands, and unmet psychiatric need amid accelerated policy momentum for psychedelic therapies.
April 20, 2026
Following an April 18 executive order, Gus Alva, MD, discusses psychedelic mechanisms, evidence, and clinical considerations for psychiatry.
October 03, 2025
Explore the latest advancements in psychiatry, including FDA updates, emerging therapies, and promising clinical trial results for mental health treatments.
October 01, 2025
This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.
September 15, 2025
MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.
